Filing Flows › Rani Therapeutics Holdings (RANI) › Q1 2026
Rani Therapeutics Holdings (RANI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the first quarter 2026 (Q1 2026), +893% from a year earlier and +17% from the quarter before. Operating margin was -488.2%, net loss $8.0M (469.3% of revenue).
Rani Therapeutics Holdings, Q1 2026: revenue $1.7M (+893% year over year), operating margin -488.2%, net loss $8.0M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | +17% | +893% |
| Operating profit | −$8.3M | — | — |
| Net earnings | −$8.0M | — | — |
| Operating cash flow | −$6.5M | -2310% | — |
What changed
Revenue was $1.7M in Q1 2026, up 893% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $8.3M, an operating margin of -488.2%. Total costs fell 18% while revenue rose 893%. The quarter ended with a net loss of $8.0M, narrower than the previous quarter's $9.1M loss. Minority interests bore $1.0M of it: to shareholders the quarter was a loss of $7.0M.
Operating cash flow was −$6.5M. Non-cash charges added back $161K of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items used $727K. Capital expenditures of $15K exceeded it, leaving free cash flow of −$6.5M.
Questions
What was Rani Therapeutics Holdings' revenue in the first quarter 2026?
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the first quarter 2026 (Q1 2026), +893% from a year earlier and +17% from the quarter before.
Was Rani Therapeutics Holdings profitable in the first quarter 2026?
Operating loss was $8.3M (-488.2% of revenue) and net loss $8.0M.